Cell Therapy News/Articles, page-10368

"IMO the “other conditions” our CEO refers to are included in the minutes of the meeting. Given their importance he chose not reveal the strongpoints of the discussion in the latest announcement."

Actually you would think if the company is aware of significant information that would impact the share price, it should release it to the market as soon as possible. That would include some change in the FDA's view of the data from the outcome from the meeting. IMO it means that the meeting produced no change from what is already known and it will have no impact on Novartis' decision. And if confidentiality conditions were being imposed by the Novartis' deal, you would expect that Novartis would be well aware or briefed about the meeting and therefore would have reached a decision already.

So... no change with the FDA as the result of the meeting and no progress with the Novartis deal as the result of the meeting is the logical conclusion.